Viking Therapeutics, Inc. - Common Stock (VKTX)

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.

Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock.

2025 is the year we learn whether Viking Therapeutics stock will be a winner.

Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard.

Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the report.

While we wait for the earnings report to be posted along with the forward guidance predictions, the chart looks interesting. 

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.

Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles.

VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington

Investors are running into Viking Therapeutics this week after an incident of drug-induced liver injury pushed Pfizer into terminating the development of its weight-loss pill.

Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.

Pfizer bows, but is not entirely out of the GLP-1 race.